Safety and tolerability profile of JEMPERLI1

Laboratory abnormalities

Laboratory Abnormalities Table. See important safety information below.

Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1–blocking antibodies.1

*Intention-to-treat population (N=104).

Consists of new onset of laboratory abnormality or worsening of baseline laboratory abnormality.

Icon: JEMPERLI Dosing and Administration

Find out how to dose and
administer JEMPERLI.

Icon: JEMPERLI Support

Get support for
JEMPERLI at every step.

Icon: JEMPERLI Trial

Explore the pivotal trial